For acute treatment
To treat a migraine attack once it’s started, the recommended dose is
1 VYDURA 75 mg tablet, not more than once daily¹

For preventive treatment

For patients with CV disease or risk factors

• VYDURA is not contraindicated in patients with cardiovascular (CV) risk factors or stable CV disease^1,2

Co-administration of medications 

• VYDURA can be co-administered with oral contraceptives³
   

VYDURA is not recommended for:

• Patients with severe hepatic impairment¹
• Patients with end-stage renal disease (creatinine clearance <15 mL/min)¹
• Concomitant use with strong inhibitors of CYP3A4¹
• Concomitant use with strong or moderate inducers of CYP3A4¹

Another dose of VYDURA within 48 hours should be avoided when it is concomitantly administered with moderate inhibitors of CYP3A4 (e.g., fluconazole).¹

Inhibitors of P-gp and BCRP efflux transporters may increase plasma concentrations of rimegepant. Another dose of VYDURA within 48 hours should be avoided when it is concomitantly administered with strong inhibitors of P-gp.¹

Medication-overuse headache (MOH)
Overuse of any type of medicinal products for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained, and treatment should be discontinued. The diagnosis of MOH should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of medicinal products for acute headache.¹